Bexagliflozin, canagliflozin, dapagliflozin, and empagliflozin are SGLT2 classical inhibitors that have been approved by the Food and Drug Administration (FDA) to treat type 2 diabetes. Here, SLC5A2 is linked to type 2 diabetes mellitus.